Patents by Inventor Corey R. Hopkins

Corey R. Hopkins has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibition of BMP signaling, compounds, compositions and uses thereof
    Patent number: 10745400
    Abstract: Provided herein are substituted imidazo[1,2-a]pyridines useful as inhibitors of BMP signaling. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted imidazo[1,2-a]pyridines.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: August 18, 2020
    Assignees: Vanderbuilt University, La Jolla Pharmaceuticals Company
    Inventors: Corey R. Hopkins, Matthew Ritter, Charles C. Hong, Anish Vadukoot, Darren W. Engers, Craig W. Lindsley
  • SUBSTITUTED 2-(4-HETEROCYCLYLBENZYL)ISOINDOLIN-1-ONE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1
    Publication number: 20200231592
    Abstract: In one aspect, the invention relates to substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M1 (mAChR M1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: March 18, 2020
    Publication date: July 23, 2020
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Michael R. Wood, Corey R. Hopkins, Bruce J. Melancon, Michael S. Poslusney, Darren W. Engers
  • Isoquinoline amide and isoquinoline amide-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
    Patent number: 10710997
    Abstract: Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4) of the following formula: synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.
    Type: Grant
    Filed: September 1, 2017
    Date of Patent: July 14, 2020
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Corey R. Hopkins, Andrew Felts, Aaron M. Bender
  • Substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs as positive allosteric modulators of the muscarinic acetylcholine receptor M1
    Patent number: 10654847
    Abstract: In one aspect, the invention relates to substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M1 (mAChR M1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: February 22, 2018
    Date of Patent: May 19, 2020
    Assignee: Vanderbilt University
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Michael R. Wood, Corey R. Hopkins, Bruce J. Melancon, Michael S. Poslusney, Darren W. Engers
  • FUSED HETEROCYCLIC COMPOUNDS AS SELECTIVE BMP INHIBITORS
    Publication number: 20200054643
    Abstract: The present invention provides small molecule inhibitors of BMP signaling that are useful for treating diseases or conditions associated with BMP signaling, including cancers of the central nervous system.
    Type: Application
    Filed: January 18, 2018
    Publication date: February 20, 2020
    Inventors: Corey R. Hopkins, Charles C. Hong, Craig W. Lindsley, Darren W. Engers
  • Indazole and azaindazole substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
    Patent number: 10526323
    Abstract: Compounds, including those of the following formula: wherein the variables are defined herein, which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: January 7, 2020
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Corey R. Hopkins, Craig W. Lindsley, Colleen M. Niswender, Darren W. Engers, Joe Panarese, Joanne Bronson, Yong-Jin Wu, Jason Guernon
  • INHIBITION OF BMP SIGNALING, COMPOUNDS, COMPOSITIONS AND USES THEREOF
    Publication number: 20190284183
    Abstract: Provided herein are substituted imidazo[1,2-a]pyridines useful as inhibitors of BMP signaling. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted imidazo[1,2-a]pyridines.
    Type: Application
    Filed: March 14, 2019
    Publication date: September 19, 2019
    Inventors: Corey R. Hopkins, Matthew Ritter, Charles C. Hong, Anish Vadulkoot, Darren Engers, Craig W. Lindsley
  • Inhibition of BMP Signaling Compounds, Compositions and Uses Thereof
    Publication number: 20190218214
    Abstract: Provided herein are substituted imidazo[1,2-a]pyridines useful as inhibitors of BMP signaling. The invention further provides pharmaceutical compositions of the compounds of the invention. The invention also provides medical uses of substituted imidazo [1,2-a] pyridines.
    Type: Application
    Filed: September 14, 2017
    Publication date: July 18, 2019
    Inventors: Corey R. Hopkins, Charles C. Hong, Craig W. Lindsley, Darren W. Engers
  • Isoquiniline and napthalene-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
    Patent number: 10227343
    Abstract: Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.
    Type: Grant
    Filed: February 1, 2016
    Date of Patent: March 12, 2019
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Colleen M. Niswender, Corey R. Hopkins, Joanne Bronson, Yong-Jin Wu, Kyle Emmitte, Joe Panarese, Darren W. Engers, Julie Engers
  • Benzothiazole and benzisothiazole-substituted compounds as mGluR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
    Patent number: 10221172
    Abstract: Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: March 5, 2019
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Corey R. Hopkins, Craig W. Lindsley, Colleen M. Niswender, Darren W. Engers, Sean Bollinger
  • Fused heterocyclic compounds as selective BMP inhibitors
    Patent number: 10196392
    Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.
    Type: Grant
    Filed: July 17, 2017
    Date of Patent: February 5, 2019
    Assignee: Vanderbilt University
    Inventors: Corey R. Hopkins, Charles C. Hong, Craig W. Lindsley, Darren W. Engers
  • SUBSTITUTED 2-(4-HETEROCYCLYLBENZYL)ISOINDOLIN-1-ONE ANALOGS AS POSITIVE ALLOSTERIC MODULATORS OF THE MUSCARINIC ACETYLCHOLINE RECEPTOR M1
    Publication number: 20180179205
    Abstract: In one aspect, the invention relates to substituted 2-(4-heterocyclylbenzyl)isoindolin-1-one analogs compounds, derivatives thereof, and related compounds, which are useful as positive allosteric modulators of the muscarinic acetylcholine receptor M1 (mAChR M1); synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating neurological and psychiatric disorders associated with muscarinic acetylcholine receptor dysfunction using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: February 22, 2018
    Publication date: June 28, 2018
    Inventors: Craig W. Lindsley, P. Jeffrey Conn, Michael R. Wood, Corey R. Hopkins, Bruce J. Melancon, Michael S. Poslusney, Darren W. Engers
  • Benzoisoxazole-substituted compounds as MGLUR4 allosteric potentiators, compositions, and methods of treating neurological dysfunction
    Patent number: 9980945
    Abstract: Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: May 29, 2018
    Assignee: Vanderbilt University
    Inventors: P. Jeffrey Conn, Corey R. Hopkins, Craig W. Lindsley, Colleen M. Niswender, Darren W. Engers, Joe Panarese, Sean Bollinger, Julie Engers
  • ISOQUINOLINE AMIDE AND ISOQUINOLINE AMIDE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION
    Publication number: 20180057491
    Abstract: Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.
    Type: Application
    Filed: September 1, 2017
    Publication date: March 1, 2018
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Corey R. Hopkins, Andrew Felts, Aaron M. Bender
  • BENZOTHIAZOLE AND BENZISOTHIAZOLE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION
    Publication number: 20180022744
    Abstract: Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.
    Type: Application
    Filed: January 13, 2016
    Publication date: January 25, 2018
    Inventors: P. Jeffrey Conn, Corey R. Hopkins, Craig W. Lindsley, Colleen M. Niswender, Darren W. Engers, Sean Bollinger
  • ISOQUINILINE AND NAPTHALENE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION
    Publication number: 20180022745
    Abstract: Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.
    Type: Application
    Filed: February 1, 2016
    Publication date: January 25, 2018
    Inventors: P. Jeffrey Conn, Craig W. Lindsley, Colleen M. Niswender, Corey R. Hopkins, Joanne Bronson, Yong-Jin Wu, Kyle Emmitte, Joe Panarese, Darren W. Engers, Julie Engers
  • INDAZOLE AND AZAINDAZOLE SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION
    Publication number: 20180022746
    Abstract: Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.
    Type: Application
    Filed: February 1, 2016
    Publication date: January 25, 2018
    Inventors: P. Jeffrey Conn, Corey R. Hopkins, Craig W. Lindsley, Colleen M. Niswender, Darren W. Engers, Joe Panarese, Joanne Bronson, Yong-Jin Wu, Jason Guernon
  • BENZOISOXAZOLE-SUBSTITUTED COMPOUNDS AS MGLUR4 ALLOSTERIC POTENTIATORS, COMPOSITIONS, AND METHODS OF TREATING NEUROLOGICAL DYSFUNCTION
    Publication number: 20180021312
    Abstract: Compounds which are useful as allosteric potentiators/positive allosteric modulators of the metabotropic glutamate receptor subtype 4 (mGluR4); synthetic methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of using the compounds, for example, in treating neurological and psychiatric disorders or other disease state associated with glutamate dysfunction.
    Type: Application
    Filed: January 13, 2016
    Publication date: January 25, 2018
    Inventors: P. Jeffrey Conn, Corey R. Hopkins, Craig W. Lindsley, Colleen M. Niswender, Darren W. Engers, Joe Panarese, Sean Bollinger, Julie Engers
  • Fused Heterocyclic Compounds as Selective BMP Inhibitors
    Publication number: 20170313701
    Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.
    Type: Application
    Filed: July 17, 2017
    Publication date: November 2, 2017
    Inventors: Corey R. Hopkins, Charles C. Hong, Craig W. Lindsley, Darren W. Engers
  • Fused heterocyclic compounds as selective BMP inhibitors
    Patent number: 9738636
    Abstract: The present invention provides small molecule inhibitors of BMP signaling. These compounds may be used to modulate cell growth, differentiation, proliferation, and apoptosis, and thus may be useful for treating diseases or conditions associated with BMP signaling, including inflammation, cardiovascular disease, hematological disease, cancer, and bone disorders, as well as for modulating cellular differentiation and/or proliferation.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: August 22, 2017
    Assignee: Vanderbilt University
    Inventors: Corey R. Hopkins, Charles C. Hong, Craig W. Lindsley, Darren W. Engers